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Abstract
Substantial basic science and clinical evidence suggests that excess tumor necrosis factor-alpha
(TNF-alpha) is centrally involved in the pathogenesis of Alzheimer's disease. In addition to its pro-
inflammatory functions, TNF-alpha has recently been recognized to be a gliotransmitter that
regulates synaptic function in neural networks. TNF-alpha has also recently been shown to mediate
the disruption in synaptic memory mechanisms, which is caused by beta-amyloid and beta-amyloid
oligomers. The efficacy of etanercept, a biologic antagonist of TNF-alpha, delivered by perispinal
administration, for treatment of Alzheimer's disease over a period of six months has been
previously reported in a pilot study. This report details rapid cognitive improvement, beginning
within minutes, using this same anti-TNF treatment modality, in a patient with late-onset
Alzheimer's disease. Rapid cognitive improvement following perispinal etanercept may be related
to amelioration of the effects of excess TNF-alpha on synaptic mechanisms in Alzheimer's disease
and provides a promising area for additional investigation and therapeutic intervention.
Background
Neuroinflammation with overexpression of cytokines is a
standard characteristic of the brain pathology present in
Alzheimer's disease [1-4]. Involvement of the pro-inflam-
matory cytokine tumor necrosis factor-alpha (TNF-alpha)
in the pathogenesis of Alzheimer's disease has long been
suspected [5-9]. Increasing basic science, genetic, and clin-
ical evidence now supports the concept that excess TNF-
alpha plays a central role in Alzheimer's disease [5-25].
In 1998 etanercept, a potent anti-TNF therapeutic, was
approved for human use, with rheumatoid arthritis as the
initial indication. Etanercept is a recombinant dimeric
fusion protein consisting of the extracellular ligand-bind-
ing portions of two human p75 TNF-alpha receptors
linked to the Fc fragment of human IgG1. Etanercept
binds to TNF-alpha and blocks its interaction with cell
surface TNF-alpha receptors, thereby reducing the bio-
logic effect of excess TNF-alpha. The medical community
now has more than 1 million patient-years of experience
using etanercept for treatment of a variety of inflamma-
tory disorders in which TNF-alpha has been postulated to
play a role [26].
In 2006 the present authors published a pilot study which
provided proof-of-concept that a novel method of admin-
istration of etanercept was efficacious for the treatment of
Alzheimer's disease [20]. This novel method, perispinal
extrathecal administration in the posterior neck, was
hypothesized to improve delivery of etanercept to the
brain via the cerebrospinal venous system[21,27]. In an
open-label study of 15 patients treated weekly for a period
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of six months, perispinal extrathecal administration of
etanercept led to sustained cognitive improvement in this
cohort of patients with probable Alzheimer's disease rang-
ing in severity from mild to severe [20]. The concept of
TNF-alpha-inhibition for the treatment of Alzheimer's
disease has been recently reviewed[22], and is supported
by additional recent publications [16,18,23-25].
The author's 2006 pilot study was an IRB-approved clini-
cal trial whose protocol included monthly cognitive test-
ing. There was no provision for testing at shorter intervals.
Nevertheless during the six-month duration of this clini-
cal trial, and now for a period of more than three years,
the authors have noted an unexpected and largely unprec-
edented clinical phenomenon, which they have observed
on a weekly basis in the majority of the patients treated.
This unexpected, but repeatedly observed phenomenon
was a noticeable clinical improvement within minutes of
perispinal etanercept administration[21]. Although this
rapid clinical improvement could not be measured using
the assessment intervals which were included in the orig-
inal clinical trial protocol, the authors recently had the
opportunity to quantitate this rapid treatment effect using
several standardized cognitive tests in a new patient
treated as part of their standard practice of medicine. This
patient is the subject of the present case report.
Synaptic dysfunction has gained increasing recognition as
an important pathophysiological component of Alzhe-
imer's disease [28-32]. Recent evidence suggests that TNF-
alpha may be involved in this synaptic dysfunction [33-
37]. Although TNF-alpha is most widely known as a pro-
inflammatory cytokine, basic science studies suggest that
TNF-alpha may also have entirely different functions in
the Alzheimer brain: as a regulator of synaptic transmis-
sion; and as a mediator of β-amyloid and β-amyloid oli-
gomer disruption of memory mechanisms [33-37].
The present report details the clinical observations in this
patient with late-onset Alzheimer's disease. It then
attempts to provide a theoretical framework to explore the
pathophysiological mechanisms underlying the rapid
improvement in the patient's behavior and cognition, par-
ticularly those involving TNF-alpha and synaptic func-
tion, which may account for the rapid clinical effects
observed after perispinal etanercept administration.
Case presentation
History of present illness
The patient is an 81 y.o. physician who was referred in
October 2007 for consideration of perispinal etanercept
treatment by his internist. The patient had been in good
general health until about two years before presentation,
at which time his wife noted progressive memory difficul-
ties and difficulties with mathematical calculation.
His wife took over check writing, and the patient was eval-
uated by a neurologist 18 months ago. Donepezil was pre-
scribed but was not tolerated and was discontinued after
four months. Memantine and rivastigmine were pre-
scribed but also were not tolerated by the patient. Galan-
tamine was begun six months prior to presentation, and
continued to the present at a dose of 8 mg per day,
reduced from a maximum attempted dose of 16 mg per
day due to side effects. No beneficial effect from the galan-
tamine has been noted by the patient's family or his pri-
mary care physician.
The patient's current medications include atorvastatin,
low dose aspirin, and galantamine 8 mg per day.
Past medical history
The patient's past medical history include a lumbar discec-
tomy and fusion performed twenty years previously, with
chronic intermittent low back pain and spinal stenosis;
hypercholesterolemia; and localized prostate cancer, suc-
cessfully treated with localized radiation without sign of
recurrence. Otherwise the past medical history was unre-
markable, with no history of diabetes, stroke, transient
ischemic attack, head trauma, epilepsy, loss of conscious-
ness, hallucinations, recent infection, demyelinating dis-
ease, or blood or bleeding disorders, lymphoma,
congestive heart failure, autoimmune disease, immuno-
suppression, tuberculosis or visual disturbance. Purified
protein derivative testing was negative. Family history of
dementia or neurodegenerative disease was negative.
Physical examination
General physical exam was unremarkable. Blood pressure
was 150/90, pulse 80 and regular, afebrile, respirations
12. The chest was clear to percussion and auscultation.
There were no cardiac murmurs and no bruits in the neck.
Neurologic examination one day prior to etanercept 
treatment
The results of neurological examination by author HG
one day prior to etanercept administration were as fol-
lows:
The cranial nerve examination II-XII was within normal
limits: the pupils were four mm, round, and reactive to
light and accommodation. The discs were flat. The visual
fields were full to confrontation; extraocular movements
were conjugate and full without nystagmus. Facial motion
and sensation were symmetrical and without deficits. The
patient was able to hear finger rustling in both ears, how-
ever his auditory processing appeared to be decreased,
and he intermittently asked for questions to be repeated.
Weber was midline, air conduction was greater than bone
conduction bilaterally, palate was normal, sternocleido-
mastoid strength was normal, trapezius strength was nor-Journal of Neuroinflammation 2008, 5:2 http://www.jneuroinflammation.com/content/5/1/2
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mal, and tongue movements were normal. Tremor was
absent.
Motor and cerebellar examination was unremarkable.
Deep tendon reflexes were as follows: biceps two plus and
symmetrical, triceps one plus and symmetrical, supinator
on the right absent, on the left one plus, quadriceps one
plus bilaterally, ankles absent on the right and one plus
on the left. Toe signs were flexor. There is no pronator
drift, abnormal involuntary movement, or Romberg.
There was symmetrical muscle tone, bulk, and develop-
ment throughout. There was normal station and gait, and
normal rapid alternating movement, normal finger to fin-
ger, and normal gait. There were no frontal release signs
except for a positive bilateral palmomental sign.
Sensory examination responses were intact throughout to
joint position, pinprick, and light touch. There was mild
decrease in vibratory sense in the right hallux only.
Mental status examination performed one day prior to
etanercept administration revealed a dignified appearing
man who appeared younger than his stated age, neatly
groomed and socially outgoing in a superficial engaging
fashion. There was no agitation, suspiciousness, or hostil-
ity. He appeared at times to be inappropriately euphoric.
He had difficulty recalling personal autobiographical
information such as birthday or his father's occupation.
He could not recall the names of any of the physicians
who treated him. He was not oriented to the calendar
date, day of the week, year, place, city, or state.
His spontaneous speech appeared fluent with normal
prosody, articulation, and rate of speech production with-
out any dysarthria. On detailed examination he had
marked anomic aphasia, i.e., when shown the first ten pic-
tures of the Boston Naming Test[38] the patient could not
name nine out of ten, but used marked circumlocution.
He was able to repeat complex sentences without diffi-
culty. On a verbal fluency task, i.e., when asked to list all
of the words that start with the letter F in 60 seconds he
listed five words with five perseveratory responses and
one neologism. When given a semantic task, i.e. asked to
list all the animals he could in 60 seconds he could only
list two, dog and cat.
The patient was able to copy a three-dimensional cube,
but when asked to draw a clock with the hands placed at
ten minutes after 11, he drew a square without numbers
and one line for the hour or minute hand [see Figure 1].
He could not do the alternating trail making task and was
clearly overwhelmed by the task [see Figure 1]. He was
able to pantomime four out of eight finger constructions
of increasing complexity.
On memory testing the patient could not recall the name
of physician HG after 90 seconds despite repetitive intro-
ductions on at least four occasions throughout the exam-
ination. It took three trials for the patient to register five
words and 90 seconds later the patient could not retrieve
any of the words even with categorical cueing. When given
multiple choice cueing he was able to retrieve two words.
On an A vigilance task, screening for sustained attention,
the patient made four errors of omission. He was able to
list five digits in a forward fashion, but could not list three
digits in a reverse fashion.
The patient could not perform simple calculations and
could not do serial sevens. When asked to add 29 plus 11
after a marked latency he said 31.
Abstract concepts such as a how a train and a bicycle, a
watch and a ruler, or music and painting were similar
could not be expressed by the patient.
On the Montreal Cognitive Assessment test (MOCA) [39]
the patient scored seven out of 30 possible points, consist-
ent with a moderate to severe cortical dementia.
The patient met the NINCDS-ADRDA Criteria for proba-
ble AD[40], and, in addition, met the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria for AD[41].
Laboratory results
MRI examination in March 2006 showed age-related dif-
fuse central and cortical atrophy. In November 2006 FDG
positron emission tomography brain scan at UCLA
showed moderate to severe cortical atrophy, with atrophy-
associated global cortical hypometabolism and superim-
posed biparietal, left temporal and posterior cingulate
cortex hypometabolism, read as consistent with Alzhe-
imer's disease.
Laboratory examination prior to treatment revealed a sta-
ble but borderline elevated blood urea nitrogen and creat-
inine, but was otherwise unremarkable, including chest x-
ray which was unremarkable, normal thyroid function,
normal liver function tests, normal complete blood
count, normal serum glucose and electrolytes, normal
prostate specific antigen, cholesterol, triglycerides, serum
folic acid and vitamin B12 levels, non-reactive RPR and
non-reactive FTA-ABS.
Treatment
Written informed consent for administration of etaner-
cept was obtained from the patient and his wife after the
potential risks of etanercept, including infection, cytope-
nias, possible increased risk of lymphoma and demyeli-Journal of Neuroinflammation 2008, 5:2 http://www.jneuroinflammation.com/content/5/1/2
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Rapid and sustained improvement in Visuospatial/Executive function following perispinal etanercept documented by the Mon- treal Cognitive Assessment Figure 1
Rapid and sustained improvement in Visuospatial/Executive function following perispinal etanercept docu-
mented by the Montreal Cognitive Assessment. The top panel depicts the first three tasks from the Montreal Cognitive 
Assessment completed by the patient one day prior to perispinal etanercept administration. The middle panel depicts the 
patient's results two hours after perispinal etanercept administration, showing correct completion of the alternating trail mak-
ing task documenting improved executive function, and improvement in depiction of a clock face. The bottom panel depicts the 
patient's results at seven weeks, fourteen days after receiving his previous dose of perispinal etanercept, showing further 
improvement in his drawing of the clock face, with numerals added, and persistence in improvement in completion of the trail 
making task. (The instruction for completion of the alternating trail making task are as follows: Please draw a line, going from a 
number to a letter in ascending order. Begin here [point to (1)] and draw a line from 1 then to A then to 2 and so on. End here [point 
to (E)]).Journal of Neuroinflammation 2008, 5:2 http://www.jneuroinflammation.com/content/5/1/2
Page 5 of 10
(page number not for citation purposes)
nating disease, death, eye inflammation, and congestive
heart failure; and alternative treatment approaches were
enumerated.
Immediately prior to etanercept administration the
patient was questioned by author ET. He could not state
the year nor could he name the state.
Twenty-five mg of etanercept in 1 cc of sterile water was
administered by posterior cervical interspinous injection
in the midline with a 27 gauge needle at the C6–7 inter-
space followed by Trendelenburg positioning with the
head dependent for five minutes, as previously described,
to effect entry of etanercept into the cerebrospinal venous
system[21,27]. The patient had no difficulty with this
positioning and resumed sitting posture without incident.
Ten minutes after dosing the patient was reexamined. He
was noticeably calmer, less frustrated, and more attentive.
He was able to correctly identify the state as California,
and he identified the year as 2006. His responses to ques-
tioning seemed less effortful and more rapid, with less
latency. He left for author HG's office for further testing.
Neurologic examination two hours after etanercept 
treatment
The patient was retested by author HG two hours after
etanercept administration. He could not recall being in
author ET's office earlier in the day, but could recall HG's
name. He was now oriented to month, day of week, and
place, and could again correctly name the state as Califor-
nia, which he could not do prior to perispinal etanercept
administration. He was off on the calendar date by two
days, and year by one year. Throughout testing he
appeared more aware of his deficient performance.
The patient's ability to name pictures was markedly
improved, correctly naming nine out of the first ten pic-
tures on the Boston Naming Test short form, requiring
phonemic cueing for three of the items (squid, bench, and
hammock), a marked improvement from the day prior
when he could only name one of the ten presented pic-
tures and used marked circumlocution. On the verbal flu-
ency FAS test he was able to list eight words that started
with the letter F in 60 seconds and made only one perse-
veratory response. On a categories semantic task he was
able to list five animals in 60 seconds.
On visuospatial functioning, the patient could copy a
three-dimensional cube, and when asked to draw a clock
he drew a circle with an hour and minute hand [see Figure
1]. When given a modified trails B test the patient was
clearly able to sequence and complete the task, alternating
letters and numbers accurately [see Figure 1]. He was able
to pantomime seven out of eight finger constructions of
increasing complexity.
On memory testing the patient could not recall any of five
memoranda after five minutes even with categorical cue-
ing. With multiple-choice cueing he could recall one out
of five memoranda. However, as mentioned he could
recall the examiner's name without difficulty and without
necessity of repetition of introductions throughout the
entire examination.
On attentional testing, the patient could accurately list
five digits in a forward fashion and three digits in a reverse
sequence fashion. On an A vigilance task he made no
errors of omission or commission.
On calculations, he could subtract seven from one hun-
dred correctly, but could not perform serial sevens. He
could not divide 58 by two, nor could he add 29 plus 11.
He could not tell physician HG how many nickels were in
a dollar.
On ability to abstract concepts he was able to relate how a
train and bicycle were similar in that they both can be
used for transportation. When asked how a watch and a
ruler were similar he related that they both give informa-
tion. When asked how music and painting were similar he
related "you draw your painting, however music you
hear".
Montreal Cognitive Assessment performed two hours fol-
lowing the single dose of perispinal etanercept yielded a
score of 15 out of 30 points [see Figure 1].
A collateral interview with the patient's son and wife con-
firmed their validation of a marked improvement in cog-
nitive abilities following perispinal etanercept
administration.
Upon returning to the clinic one week following perispi-
nal etanercept administration for his weekly dose the
patient's wife and son confirmed that he had remained
markedly clinically improved throughout the week, a fact
which was remarked upon by the family [see Additional
file 1]. He was noticed to be less reluctant to join in con-
versation. On re-examination by author ET prior to repeat
dosing one week after the initial dose, the patient correctly
identified the year, month, season, day of week and state.
He appeared to answer with less frustration, and the
examiner's impression was that there was reduced latency
of response, and his affect seemed improved. On the FAS
test for verbal fluency when asked to list all of the words
that start with the letter F in 60 seconds he listed 8 words,
and named 5 animals in 60 seconds. The patient received
a single dose of perispinal etanercept for each of the firstJournal of Neuroinflammation 2008, 5:2 http://www.jneuroinflammation.com/content/5/1/2
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five weeks; the next dose was omitted, and the patient
returned after seven weeks and was retested. At seven
weeks, fourteen days after receiving his last dose of perisp-
inal etanercept, his Montreal Cognitive Assessment score
was 14, with persistent improvement in the trail making
task, and improved depiction of the clock face [see Figure
1].
Discussion
The authors' preferred hypothesis to explain the rapid
clinical improvement observed centers on the emerging
evidence, which suggests that TNF-alpha is of critical
importance in the regulation of synaptic transmission in
the brain. The authors are led in this direction by the com-
bination of:
1. The extreme rapidity of the effect;
2. The extraordinary potency and selectivity of etanercept
as an anti-TNF-alpha agent, due to its biologic nature and
molecular structure;
3. The various lines of scientific evidence which have sug-
gested that synaptic dysfunction may be of key impor-
tance in the pathogenesis of Alzheimer's disease [28-32];
4. Evidence suggesting that TNF-alpha regulates synaptic
transmission in the brain[33-35,42,43]; and,
5. Evidence suggesting that TNF-alpha mediates the syn-
aptic dysfunction underlying cognitive and behavioral
impairment produced by both beta-amyloid and beta-
amyloid oligomers [36,37].
A weakness of the present study is the fact that all partici-
pants, including the examining physicians, were aware of
the treatment modality utilized, which could, potentially,
bias the results, and a placebo effect cannot be ruled out.
However, it should be noted that the clinical, cognitive,
and behavioral improvement in the present patient was
noted by the patient's family members, family friends,
and both authors, and confirmed by the use of several
objective measures.
The eight point improvement on the MOCA, from a score
of seven to a score of 15, is notable because it exceeds the
normal test-retest variation (0.9+/-2.5 points[44]) by
more than three standard deviations. The MOCA was
designed to measure eight cognitive domains, and is par-
ticularly sensitive to changes in executive function[44].
This is illustrated by the patient's results on the trail-mak-
ing portion of the test, as well as in depicting a clock face
[see Figure 1].
Improved verbal fluency, as suggested by this patient's
improvement in category naming, animal naming, and
Boston Naming results, is a characteristic effect of perispi-
nal etanercept, in the authors' experience. This has been
particularly noticeable in patients with probable Alzhe-
imer's disease, such as the present patient, who present
with difficulties in word finding, which has included one
patient with primary progressive aphasia treated by the
authors. Improved behavior, and improvement in affect,
as seen in this patient, is another characteristic effect of
perispinal etanercept in the authors' experience.
It should also be emphasized that rapid cognitive
improvement following perispinal etanercept is not lim-
ited to the patient of the present report, but has, in fact,
been commonly observed in multiple patients during the
authors' now more than three year clinical experience uti-
lizing perispinal etanercept for treatment of probable
Alzheimer's disease[20,21]. The rapid response to perisp-
inal etanercept may provide an important clue to the
pathophysiologic mechanisms underlying not only
Alzheimer's disease, but also other brain disorders involv-
ing excess TNF-alpha and cognitive dysfunction, includ-
ing frontotemporal dementia[45], and traumatic brain
injury [46].
Complex problem solving requires intact pre-frontal and
anterior cingulate function allowing recall of appropriate
and relevant past, present, and future deeds, assigning
emotional valence to them and comparing them to the
present situation to manage an anticipated sequence of
events in a flexible and goal-oriented fashion. Prefrontal
neuropathological change of diverse etiologies, including
Alzheimer's disease interferes with such complex func-
tions. The assessment of such executive dysfunction is
poorly reflected in most standard screening psychomet-
rics. Multiple authors have commented on patients with
frontal lobe deficits that perform well on most standard-
ized psychometric tests but have incapacitating disability
to function in a real, complex life environment [47,48].
The screening of isolated cognitive domains without
screening for executive dysfunction, by simple tests such
as the Mini-Mental Status Examination or Cognitive Abil-
ities Screening Instrument, can easily miss critical deficits
in executive functioning in patients with involvement of
the anterior cingulate and pre-frontal lobes.
Executive dysfunction is one of the chief components of
the final common pathway of disabilities in Alzheimer's
disease that appear to rapidly improve with perispinal
etanercept as documented above. Without quantifying
executive function, a clinician or family observation of an
improvement in a patient's ability or behavior may
improperly be discounted as a subjective interpretation.
The Montreal Cognitive Assessment has several screens forJournal of Neuroinflammation 2008, 5:2 http://www.jneuroinflammation.com/content/5/1/2
Page 7 of 10
(page number not for citation purposes)
executive dysfunction, including a modified Trails B
(alternating trail making task) [see Figure 1] that reflect
the quantum improvement noted in the present patient,
thereby objectifying the patient's family and clinicians'
subjective impressions.
Innate immune regulation of brain function is an area of
intense current interest [34,42,43,49-51]. The rapid clini-
cal improvement which is characteristic of Alzheimer
patients treated with perispinal etanercept and which is
described herein provides a new clue for investigating
these mechanisms. One suspects that this rapid clinical
effect is related to the role of TNF-alpha as a regulator of
synaptic mechanisms in the brain, which was first
described more than a decade ago[52]. Glia are now
known to envelop neuronal synapses in the brain and
release molecules, gliotransmitters, which regulate synap-
tic transmission in those enveloped synapses[42,50].
TNF-alpha is one of only a handful of recognized gli-
otransmitters[33,34,42,50]. In experimental models,
TNF-alpha alters synaptic transmission in rat hippocam-
pal slices, and produces a rapid exocytosis of AMPA recep-
tors in hippocampal pyramidal cells [35,52]. TNF-alpha
released by glia, has been demonstrated to control synap-
tic strength[33,34,53,54].
Synaptic scaling has been suggested to be centrally
involved in the synaptic dysfunction occurring in Alzhe-
imer's disease[30,55]. Synaptic scaling involves uniform
adjustments in the strength of all synaptic connections for
a neuron in response to changes in the neuron's electrical
activity[34,53,54]. Synaptic scaling is a homeostatic
mechanism which is necessary for the optimal function-
ing of neural networks [34,53,54]. Synaptic scaling has
been demonstrated to be regulated by glial TNF-
alpha[34]. These experimental findings, together with the
rapid effects of perispinal etanercept shown here, con-
verge to suggest that synaptic dysregulation produced by
excess TNF-alpha [5,7-10,12,14,16,18,23] contributes to
cognitive and behavioral dysfunction in Alzheimer's dis-
ease. Furthermore, our findings suggest that this synaptic
dysfunction may, at least in part, be reversible with ana-
tomically targeted anti-TNF-alpha treatment.
Of relevance to the present report is recent evidence that
stimulation of a single neuron can cause a change in an
animal's behavior[56]. This may be possible because of
the massively interconnected nature of the brain: a single
cortical pyramidal cell connects to several thousand post-
synaptic neurons[56]. In addition, the processes of one
astrocyte may make contact with over 100,000 synapses
[50]. Processes affecting glial-neuronal interaction may
therefore have potential for rapid amplification of their
cognitive and behavioral effect.
One may therefore extrapolate from these findings and
theorize how perispinal etanercept might have rapid
widespread effects.
The authors hypothesize that excess TNF-alpha in Alzhe-
imer's disease[5,7-10,12,14,16,18,23] interferes with the
synaptic regulatory functions of TNF-alpha. When TNF-
alpha is in a normal physiologic range synaptic scaling is
enabled, thereby preserving optimal functioning of the
brain's neural network. When TNF-alpha is overexpressed,
due to glial activation, it is postulated that the synaptic
regulatory activities of TNF-alpha are disturbed. Synaptic
dysfunction is hypothesized to result from this dysregula-
tion, which may provide a basis for reduced functional
connectivity between brain regions in Alzheimer's disease
[57,58]. The rapid effects of perispinal etanercept are
hypothesized to be the result of rapid neutralization of
excess TNF-alpha, which thereby ameliorates this synaptic
dysregulation, allowing normal cross talk between differ-
ent regions of the brain.
A cytokine concentration-dependent duality of physio-
logic effect, which the authors hypothesize occurs in TNF-
alpha modulation of synaptic function, has been
observed with respect to interleukin-1(IL-1) regulation of
long-term potentiation in hippocampal slices[59]. This
data suggests that IL-1 is required for LTP under physio-
logical conditions, but at higher doses, as may be encoun-
tered in certain pathological conditions, IL-1 inhibits
LTP[59]. The authors suggest that a similar duality occurs
with respect to TNF-alpha in Alzheimer's disease.
It is speculated, on the basis of the clinical results
observed and the studies cited above, that optimal synap-
tic function in the human brain requires that TNF-alpha
remain within a physiologic range; perhaps analogous to
the necessity to maintain serum calcium in a narrow phys-
iologic range to preserve optimal neuronal function. The
positive clinical effects the authors have observed using
perispinal etanercept for chronic treatment of Alzheimer's
disease on an open-label basis [20,21], now for a period
exceeding three years, suggest that maintenance anti-TNF-
alpha treatment may have prolonged beneficial effects. It
is hoped that future studies may clarify if maintenance
perispinal etanercept treatment will help to maintain or
restore TNF-alpha homeostasis in the brain and/or cere-
brospinal fluid in patients with Alzheimer's disease.
Excess TNF-alpha now appears to preliminarily satisfy the
neurologic equivalent of Koch's postulates [60] with
respect to being an important component of the patho-
physiology of Alzheimer's disease, in that scientific evi-
dence of the following has been published:Journal of Neuroinflammation 2008, 5:2 http://www.jneuroinflammation.com/content/5/1/2
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1. Excess TNF-alpha, at a level 25 times higher than con-
trols, has been documented in the cerebrospinal fluid of
patients with Alzheimer's disease(AD); and elevated CSF
TNF-alpha correlated with progression from mild cogni-
tive impairment to AD [7-9];
2. Examination of TNF-alpha polymorphisms in popula-
tion studies has provided evidence that genetic polymor-
phisms associated with increased TNF-alpha production
are associated with increased AD risk and decreased age of
AD onset [10,16,18];
3. Increased spontaneous production of TNF-alpha by
peripheral blood mononuclear cells was associated with
increased AD risk in a population of patients followed as
part of the Framingham study[23];
4. Multiple basic science studies suggest the involvement
of TNF-alpha in neuroinflammatory mechanisms which
may contribute to AD pathogenesis
[5,6,11,15,17,19,24,25,33-37,51,61-72];
5. TNF-alpha is a gliotransmitter[33-35,42,50,51];
6. Glial TNF-alpha may regulate synaptic mechanisms
involving synaptic function in neural networks[33-35,50-
54];
7. Disruption of memory mechanisms by beta-amyloid
and beta-amyloid oligomers is mediated by TNF-alpha
[36,37]; and
8. Pilot evidence supporting the efficacy of anatomically
targeted[27] anti-TNF-alpha treatment for Alzheimer's
disease has recently been published[20,21].
The case presented here provides clinical evidence of a
rapidly reversible, TNF-alpha-related component to the
cognitive dysfunction present in Alzheimer's disease. This
reversible mechanism necessarily precedes irreversible
neuronal structural damage, somewhat analogous to the
reversible ischemic penumbra that surrounds cerebrovas-
cular infarction. The rapid treatment response is consist-
ent with emerging evidence suggesting that glial-derived
TNF-alpha may regulate brain synaptic mechanisms.
These mechanisms are worthy of further investigation,
and may lead to earlier therapeutic intervention which
may have the potential to favorably affect the natural his-
tory of Alzheimer's disease.
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